Top Story

FDA approves 9-valent HPV vaccine for certain cancers

December 10, 2014

The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of anal, cervical, vaginal and vulvar cancers.

The recombinant HPV 9-valent vaccine (Gardasil 9, Merck) covers nine HPV types, which is five more than the quadrivalent HPV vaccine (Gardasil).

Increased hospital-based services for ovarian cancer highlight need for end-of-life plans

December 4, 2014
Although the receipt of hospice care has increased over time among older patients with ovarian cancer, the rates for ICU admissions, hospitalizations and emergency…
In the Journals

Olaparib induced tumor response in patients with germline BRCA1/BRCA2 mutations

December 1, 2014
Olaparib monotherapy induced responses across tumor types in patients with germline BRCA1 or BRCA2 mutations, according to results of a multicenter phase 2 study.The…
William Maisel, MD, MPH FDA News

FDA warns against laparoscopic power morcellation for hysterectomy, myomectomy

November 24, 2014
The FDA today released an “immediately in effect” guidance that recommends laparoscopic power morcellators list a boxed warning and two contraindications on…
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Karen Midthun, MD FDA approvals

FDA approves 9-valent HPV vaccine for certain cancers

December 10, 2014
The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of…

Increased hospital-based services for ovarian cancer highlight need for end-of-life plans

December 4, 2014
Although the receipt of hospice care has increased over time among older patients with ovarian cancer, the rates for ICU admissions, hospitalizations…
In the Journals

Olaparib induced tumor response in patients with germline BRCA1/BRCA2 mutations

December 1, 2014
Olaparib monotherapy induced responses across tumor types in patients with germline BRCA1 or BRCA2 mutations, according to results of a multicenter…
William Maisel, MD, MPH FDA News

FDA warns against laparoscopic power morcellation for hysterectomy, myomectomy

November 24, 2014
The FDA today released an “immediately in effect” guidance that recommends laparoscopic power morcellators list a boxed warning and two…
Meeting News Coverage

HPV vaccination rates among girls lowest in states with highest cervical cancer rates

November 20, 2014
The percentage of girls who receive HPV vaccinations is considerably lower in states that have higher rates of cervical cancer incidence and…

Cidofovir, imiquimod effective alternatives to surgery for vulval intraepithelial neoplasia

November 18, 2014
Topical cidofovir and imiquimod appeared safe and effective alternatives to surgery for women with grade 3 vulval intraepithelial neoplasia…
Sandra Horning, MD FDA approvals

FDA approves Avastin for platinum-resistant, recurrent ovarian cancer

November 14, 2014
The FDA today approved bevacizumab for use in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian…
Ileana Arias, PhD In the JournalsPerspective

More than 8 million American women unscreened for cervical cancer

November 6, 2014
An estimated 8.2 million US women have not undergone cervical cancer screening within the past 5 years, and that statistic highlights the need to…
Charles S. Fuchs, MD In the Journals

Novel mutation detected in nearly 20% of colorectal, endometrial cancers

October 26, 2014
Somatic mutations of RNF43 were detected in nearly one of every five colorectal cancers and endometrial cancers, a finding that suggests the novel…
In the JournalsPerspective

Maintenance pazopanib extended PFS, not OS in ovarian cancer

October 24, 2014
Maintenance therapy with pazopanib extended PFS by about 45% among women with ovarian cancer whose disease did not progress during first-line…
More Headlines »